Vermillion, Inc. (NASDAQ:VRML) CFO Robert Harry Beechey acquired 25,000 shares of the firm’s stock in a transaction dated Thursday, December 6th. The shares were purchased at an average price of $0.57 per share, with a total value of $14,250.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
VRML opened at $0.52 on Friday. Vermillion, Inc. has a twelve month low of $0.45 and a twelve month high of $2.10. The company has a current ratio of 5.28, a quick ratio of 5.23 and a debt-to-equity ratio of 0.14.
Vermillion (NASDAQ:VRML) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Vermillion had a negative net margin of 392.83% and a negative return on equity of 174.33%. The company had revenue of $0.77 million during the quarter.
COPYRIGHT VIOLATION WARNING: “Robert Harry Beechey Purchases 25,000 Shares of Vermillion, Inc. (VRML) Stock” was published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://baseballnewssource.com/2018/12/08/robert-harry-beechey-purchases-25000-shares-of-vermillion-inc-vrml-stock/3065209.html.
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
See Also: Fundamental Analysis
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.